Immatics N.V. business relationships

Companies named in Immatics N.V.’s 20-F filed 2026-03-05, and public companies whose annual reports name Immatics N.V.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 5.4 / 10
AI naming: 72 / 100
Agent readiness: 5 / 100
AI adoption: 0 / 100

Named in Immatics N.V.’s annual report 5

BRISTOL MYERS SQUIBB CO (BMY)Partner7.7
“On December 12, 2024, we received the notice of termination by Bristol Myers Squibb for the collaboration regarding Allo ("BMS Allo").” SEC filing
Moderna, Inc. (MRNA)Customer6.1
“Immatics concluded that the Clinical Combination is not a contract with a customer and should not be accounted for under IFRS 15, due to the fact that Moderna does not act as a customer and Immatics does not act as a vendor with regard to the Clinical Combination.” SEC filing
Moderna, Inc. (MRNA)Licensor6.1
“Unlike IMA402 and IMA401, this TCER, in-licensed by Moderna, is not administered as protein-based biologic but is encoded in Moderna's proprietary mRNA delivery system enabling in vivo production of the TCER molecule by the patient's own body.” SEC filing
GENMAB A/S (GMAB)Partner6.1
“...wo revenue-generating strategic collaboration agreements in place with Moderna and BMS, after the termination of the collaboration agreement IMA401 ("BMS IMA401") and Allo ("BMS Allo"), as well as the termination of the collaboration agreement with Genmab A/S, Copenhagen /Denmark ("Genmab") in 2024.” SEC filing
Moderna, Inc. (MRNA)Partner6.1
“We achieved a €4.3 million ($5.0 million) milestone from our collaboration partner Moderna in December 2025, related to a contract modification.” SEC filing

Companies whose annual reports name Immatics N.V. 1

Moderna, Inc. (MRNA)names it as partner6.1
“We have entered into additional collaborations where we have agreed to provide funding in areas where we believe we can leverage our mRNA technology, such as our collaboration with Immatics N.V. to pioneer novel and transformative therapies for cancer patients with high unmet medical need.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.